Search results for " PORTAL HYPERTENSION"

showing 10 items of 11 documents

Impact of Tips Preliver Transplantation for the Outcome Posttransplantation

2008

The effects of transjugular intrahepatic portocaval shunt (TIPS) on the survival of grafts and patients after liver transplantation (LTx) have only been documented in small series and with only a comparative description with non-TIPS recipients. We evaluated 61 TIPS patients who had a subsequent LTx and compared these with 591 patients transplanted with cirrhosis without TIPS. Pretransplant characteristics were similar between groups. Graft survival at 1, 3 and 5 years post-LTx was 85.2%, 77% and 72.1% (TIPS) and 75.3%, 69.8% and 66.1% (controls). Patient survival at the same points was 91.7%, 85% and 81.7%, respectively (TIPS) and 85.4%, 80.3% and 76.2% (controls). Cox regression showed th…

AdultMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentLiver transplantationlaw.inventionPostoperative ComplicationslawmedicineTransjugular IntrahepaticHumansImmunology and AllergyPharmacology (medical)Prospective StudiesPortasystemic ShuntSurvival analysisTransplantationbusiness.industryProportional hazards modelLiver transplantation portal hypertension TIPSStentMiddle Agedmedicine.diseaseAdult; Female; Humans; Male; Middle Aged; Postoperative Complications; Prospective Studies; Survival Analysis; Liver Transplantation; Portasystemic Shunt Transjugular Intrahepatic; Treatment OutcomeSurvival AnalysisIntensive care unitLiver TransplantationSurgeryTransplantationTreatment OutcomePortal hypertensionFemalePortasystemic Shunt Transjugular IntrahepaticbusinessAmerican Journal of Transplantation
researchProduct

Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment

2021

International audience; Background & aims: Based on platelets and liver stiffness measurements, the Baveno VI criteria (B6C), the expanded B6C (EB6C), and the ANTICIPATE score can be used to rule out varices needing treatment (VNT) in patients with compensated chronic liver disease. We aimed to improve these tests by including data on the ratio of platelets to liver stiffness.Methods: In a retrospective analysis of data from 10 study populations, collected from 2004 through 2018, we randomly assigned data from 2368 patients with chronic liver disease of different etiologies to a derivation population (n = 1579; 15.1% with VNT, 50.2% with viral hepatitis, 28.9% with nonalcoholic fatty liver …

Blood PlateletsLiver CirrhosisNoninvasive Diagnosismedicine.medical_specialtyCirrhosis[SDV]Life Sciences [q-bio]PopulationEsophageal and Gastric VaricesChronic liver diseaseSeverity of Illness IndexGastroenterologyEnd Stage Liver Disease03 medical and health sciencesLiver disease0302 clinical medicineModel for End-Stage Liver DiseaseEsophageal varicesInternal medicineNonalcoholic fatty liver diseasemedicineHumanseducationBaveno VI CriteriaRetrospective Studieseducation.field_of_studyHepatologybusiness.industryGastroenterologyRetrospective cohort studyPortal Hypertensionmedicine.disease3. Good healthMELDCirrhosis030220 oncology & carcinogenesisElasticity Imaging Techniques030211 gastroenterology & hepatologybusinessBaveno VI Criteria Blood Platelets Cirrhosis Elasticity Imaging Techniques End Stage Liver Disease Esophageal and Gastric Varices Humans Liver Cirrhosis MELD Noninvasive Diagnosis Portal Hypertension Retrospective Studies Severity of Illness Index
researchProduct

LIVER RELATED EVENTS AND SURVIVAL IN PATIENTS WITH COMPENSATED HCV CIRRHOSIS: THE ROLE OF SUSTAINED VIROLOGICAL RESPONSE TO PEG-IFN BASED THERAPY AND…

2011

HCV Cirrhosis SVR PEG IFN PORTAL HYPERTENSION
researchProduct

Imaging-guided interventions modulating portal venous flow: Evidence and controversies

2021

Portal hypertension is defined by an increase in the portosystemic venous gradient. In most cases, increased resistance to portal blood flow is the initial cause of elevated portal pressure. More than 90% of cases of portal hypertension are estimated to be due to advanced chronic liver disease or cirrhosis. Transjugular intrahepatic portosystemic shunts, a non-pharmacological treatment for portal hypertension, involve the placement of a stent between the portal vein and the hepatic vein or inferior vena cava which helps bypass hepatic resistance. Portal hypertension may also be a result of extrahepatic portal vein thrombosis or compression. In these cases, percutaneous portal vein recanalis…

HepatologyGastroenterologyInternal MedicineImmunology and AllergyALPPS associating liver partition and portal vein ligation for staged hepatectomy transjugular intrahepatic portosystemic shunt BSG British Society of Gastroenterology EASL European Association for the Study of the Liver FLR future liver remnant HE hepatic encephalopathy NCBA N-butyl cyanoacrylate PH portal hypertension PVE portal vein embolisation PVR portal vein recanalisation TIPS transjugular intrahepatic portosystemic shunt Portal vein interventions TACE trans-arterial chemoembolization portal vein recanalization RCT randomised controlled trial portal vein embolization portal hypertension image guidedJHEP Reports
researchProduct

Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

2018

Background Evidence is scarce on the efficacy of long-term human albumin (HA) administration in patients with decompensated cirrhosis. The human Albumin for the treatmeNt of aScites in patients With hEpatic ciRrhosis (ANSWER) study was designed to clarify this issue. Methods We did an investigator-initiated multicentre randomised, parallel, open-label, pragmatic trial in 33 academic and non-academic Italian hospitals. We randomly assigned patients with cirrhosis and uncomplicated ascites who were treated with anti-aldosteronic drugs (≥200 mg/day) and furosemide (≥25 mg/day) to receive either standard medical treatment (SMT) or SMT plus HA (40 g twice weekly for 2 weeks, and then 40 g weekly…

Liver CirrhosisMaleTime FactorsCirrhosisKaplan-Meier Estimatelaw.inventionascites0302 clinical medicineHepatorenal syndromeRandomized controlled trialFurosemidelawAscitesClinical endpointParacentesisDiureticsalbumin decompensated cirrhosiMineralocorticoid Receptor AntagonistsSettore MED/12 - GastroenterologiaMedicine (all)Hazard ratioGeneral MedicineMiddle AgedSurvival RateCirrhosis030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyQuality-Adjusted Life Yearsmedicine.symptomHyponatremiamedicine.medical_specialty03 medical and health sciencesAlbuminsInternal medicinemedicineHumansSurvival ratealbuminAgedbusiness.industrycirrhosis; albumin; ascitesmedicine.diseaseClinical trialalbumin cirrhosis ascites liver decompensationQuality of LifeHyperkalemiabusinessEsophagus Varices Portal Hypertension Varicosis
researchProduct

Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience

2019

INTRODUCTION: The Baveno VI consensus guidelines and an expanded algorithm suggest that transient elastography (TE) and platelet (PLT) count can be used to identify patients with cirrhosis who can avoid esophagogastroduodenoscopy (EGD). The primary aims of this study were to assess the ability of a simple algorithm, which uses only laboratory parameters, to predict medium/large esophageal varices (EV) in patients with hepatitis C virus (HCV) and cirrhosis from the Rete Sicilia Selezione Terapia-HCV (RESIST-HCV) cohort and to compare the performance of the algorithm with Baveno VI and Expanded Baveno VI criteria. The secondary aim was to assess the role of TE in ruling out large EV. METHODS:…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisBAVENO VI CRITERIA PORTAL-HYPERTENSION CONSENSUS WORKSHOP LIVER STIFFNESS PLATELET COUNT CIRRHOSIS DIAGNOSIS;Esophageal and Gastric Varices03 medical and health sciences0302 clinical medicineRESIST-HCVmedicineesophageal varicesHumansBaveno VIEndoscopy Digestive SystemSerum AlbuminAgedHepatologymedicine.diagnostic_testPlatelet CountEsophagogastroduodenoscopybusiness.industryfungiGastroenterologyReproducibility of Resultsfood and beveragesHepatitis C ChronicMiddle Agedmedicine.diseasetransient elastographyEndoscopyLogistic ModelsCIRRHOSIS PORTAL HYPERTENSION VARICES STIFFNESS030220 oncology & carcinogenesistransient elastography esophageal varices HCV RESIST-HCV Baveno VIMultivariate AnalysisHCVElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologyRadiologyGastrointestinal HemorrhagebusinessVaricesTransient elastographyAlgorithms
researchProduct

Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (…

2021

Abstract Portal hypertension and ascites are two crucial events in the natural history of liver cirrhosis, whose appearance marks a downward shift in the prognosis of the disease. Over the years, several international and national societies have issued clinical practice guidelines for the diagnosis and management of portal hypertension and ascites. The present document addresses the needs of an updated guidance on the clinical management of these conditions. Accordingly, the AISF Governing Board appointed a multi-disciplinary committee of experts for drafting an update of the most recent EASL Clinical Practice Guidelines. The aim of this work was to adapt the EASL recommendations to nationa…

Liver CirrhosisPopulationScopusDiseaseEsophageal varicesAscitesHypertension PortalMedicineHumanseducationPortal hypertensioneducation.field_of_studyVariceal bleedingHepatologyEsophageal varicebusiness.industryGastroenterologyAscitesmedicine.diseaseAcute kidney injuryClinical PracticeNatural historyVariceal bleeding.ItalyAcute kidney injury; Ascites; Esophageal varices; Hepatorenal syndrome; Portal hypertension; Variceal bleeding; Ascites; Humans; Hypertension Portal; Italy; Liver CirrhosisHypertensionAscitePortal hypertensionHepatorenal syndromePortalMedical emergencymedicine.symptombusinessResource utilizationHuman
researchProduct

Diagnostica non invasiva delle varici esofagee nei pazienti con cirrosi epatica: dati ecografici vs dati endoscopici

2008

The aim of this study was to identify possible clinical, biochemical or instrumental markers which can predict in a non-invasive manner the presence of EV. One hundred and fifty-eight consecutive liver cirrhotic patients seen at our outpatient clinic were included in this study. The diagnosis of LC was done on liver biopsy findings or based on instru m e n t a l , clinical and serological data. Patients underwent EGE, ultra - sound of the upper abdomen, Doppler of the main splancnic vessels and the main parameters of liver function were tested. Liver cirrhosis was mostly correlated to hepatitis C virus and most patients were class A according to Child. At EGE, EV w e re absent in 41 patient…

Liver cirrhosis esophageal varices ultrasound esophago-gastro-duodenoscopy portal hypertension
researchProduct

EFFETTI DELLA TERAPIA CON DIRECT ACTING ANTIVIRALS (DAAS) SUI PARAMETRI ECOGRAFICI DI IPERTENSIONE PORTALE

2017

Obiettivi dello studio: Tra gli end point della terapia antivirale con DAAs nella cirrosi HCV (LCHCV) oltre all' eradicazione del virus vi sono: la regressione della fibrosi e dell’ipertensione portale. Abbiamo valutato in pazienti LCHCV e risposta sostenuta (SVR) alla terapia con DAAs il comportamento dell’AST to Platelet Ratio Index (APRI) (marker indiretto di fibrosi) e di due segni ecografici di ipertensione portale: calibro della vena porta (cVP) e diametro longitudinale della milza (DLM). Materiali: 98 pazienti con LCHCV,al Baseline (BL) a fine terapia (FT) e tre mesi (PostT3) e 9 mesi dopo la fine della terapia (PostT9) eseguivano i test di funzionalità epatica e la conta piastrinica…

Settore MED/09 - Medicina InternaDIRECT ACTING ANTIVIRALS EPATITI CRONICHE CIRROSI IPERTENSIONE PORTALE ECOGRAFIADIRECT ACTING ANTIVIRALSChronic hepatitis Liver Cirrhosis Portal Hypertension Ultrasound
researchProduct

Effects of direct-acting antiviral therapy (DAAS) on the ultrasound parameters of portal hypertension

2018

Background:Among the endpoints of antiviral therapy with DAAs in HCV related liver cirrhosis (LC-HCV) in addition to the eradication of the virus there are the regression of fibrosis and of portal hypertension. For this reason we evaluated in LC-HCV patients and sustained virological response (SVR) to DAAs therapy the behavior of the AST to Platelet Ratio Index (APRI) (indirect marker of fibrosis) and of two ultrasound (US) signs of portal hypertension: caliber of the portal vein (cPV ) and longitudinal diameter of the spleen (LDS) Methods:132 patients with LC-HCV at baseline (BL), at three months (PostT3) and 12 months (PostT12) after the end of therapy, performed liver function tests and …

Settore MED/09 - Medicina InternaDirect-acting antiviral therapy DAAs ultrasound parameters portal hypertension
researchProduct